ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma
Chiao‐En Wu(Chang Gung University), John Lunec(Newcastle University)
Cited by 39
Related Papers
Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma
|British Journal of Cancer|2017|63
Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2
|British Journal of Cancer|2004|53
<i>TP53</i> mutant <i>MDM2</i>-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation
|Oncotarget|2016|21
Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition
|International Journal of Molecular Sciences|2023|15